Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]

G. Perea, A. Lasa, A. Aventín, A. Domingo, N. Villamor, M. Paz Queipo de Llano, A. Llorente, J. Juncà, C. Palacios, C. Fernández, M. Gallart, L. Font, M. Tormo, L. Florensa, J. Bargay, J. M. Martí, P. Vivancos, P. Torres, J. J. Berlanga, I. BadellS. Brunet, J. Sierra, J. F. Nomdedéu

Research output: Contribution to journalArticleResearchpeer-review

131 Citations (Scopus)


Most patients with acute myeloid leukemia (AML) and t(8;21) or inv(16) have a good prognosis with current anthracycline- and cytarabine-based protocols. Tandem analysis with flow cytometry (FC) and real-time RT-PCR (RQ-PCR) was applied to 55 patients, 28 harboring a t(8;21) and 27 an inv(16), including one case with a novel CBFbeta/MYH11 transcript. A total of 31% (n=17) of CR patients relapsed: seven with t(8;21) and 10 with inv(16). The mean amount of minimal residual disease (MRD) detected by FC in relapsed and nonrelapsed patients was markedly different: 0.3 vs 0.08% (P=0.002) at the end of treatment. The mean number of fusion transcript copies/ABL×104 also differed between relapsed and non-relapsed patients: 2385 vs 122 (P=0.001) after induction, 56 vs 7.6 after intensification (P=0.0001) and 75 vs 3.3 (P=0.0001) at the end of chemotherapy. Relapses were more common in patients with FC MRD level >0.1% at the end of treatment than in patients with ≤0.1%: cumulative incidence of relapse (CIR) was 67 and 21% (P=0.03), respectively. Likewise, using RQ-PCR, a cutoff level of >10 copies at the end of treatment correlated with a high risk of relapse: CIR was 75% for patients with RQ-PCR >10 compared to 21% for patients with RQ-PCR levels ≤10 (P=0.04). Combined use of FC and RQ-PCR may improve MRD detection, and provide useful clinical information on relapse kinetics in AML patients. © 2006 Nature Publishing Group All rights reserved.
Original languageEnglish
Pages (from-to)87-94
Issue number1
Publication statusPublished - 1 Jan 2006


  • Flow cytometry
  • Leukemia
  • Minimal residual disease
  • Molecular methods


Dive into the research topics of 'Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]'. Together they form a unique fingerprint.

Cite this